<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="synthesised brominated and phosphonated compounds against a panel of human" exact="cancer" post="cell lines (A2780, MCF-7, MDA-MB 231) were investigated by"/>
 <result pre="Drugs that interfere with tubulin polymerisation/depolymerisation dynamics might lead to" exact="suppression" post="of the cell growth7â€&quot;9. Drugs that target the MT"/>
 <result pre="cell growth-inhibitory properties of 3-[(1-benzyl-1,2,3-triazol-4-yl)methoxy]-D-secoestrones against certain cervical, breast, and" exact="ovarian cancer" post="cells was carried out. The determination of structureâ€&quot;activity relationship"/>
 <result pre="growth-inhibitory properties of 3-[(1-benzyl-1,2,3-triazol-4-yl)methoxy]-D-secoestrones against certain cervical, breast, and ovarian" exact="cancer" post="cells was carried out. The determination of structureâ€&quot;activity relationship"/>
 <result pre="1, 17Î²-HSD1) involved in oestrogen biosynthesis. Concerning oestrogen-dependent diseases, the" exact="suppression" post="of local oestrogen production might serve as an effective"/>
 <result pre="ovarian (A2780) and two breast (MCF-7 and MDA-MB-231) human adherent" exact="cancer" post="cell lines. As a general tendency, ovarian cell line"/>
 <result pre="not exert considerable growth inhibitory action against MDA-MB-231 cells. The" exact="cancer" post="selectivity of compound 12a was tested by means of"/>
 <result pre="(28.73â€‰Â±â€‰1.26% and 37.94â€‰Â±â€‰0.75% in 10 and 30â€‰ÂµM, respectively) indicating the" exact="cancer" post="selective property of the determined antiproliferative action. Table 1."/>
 <result pre="the newly synthesised 12a owing the lowest IC50 value against" exact="ovarian cancer" post="cell line A2780, 12a was supposed to influence microtubule"/>
 <result pre="newly synthesised 12a owing the lowest IC50 value against ovarian" exact="cancer" post="cell line A2780, 12a was supposed to influence microtubule"/>
 <result pre="synthesise new 13Î±-oestrone derivatives as potent antiproliferative agents against human" exact="cancer" post="cell lines of reproductive origin. Our strategy included the"/>
 <result pre="recently, that compound 4a displayed outstanding antiproliferative action against certain" exact="cancer" post="cell lines; however, its para-t-Bu counterpart 4b did not"/>
 <result pre="influenced the growth of A2780 cells most. Considering the two" exact="breast cancer" post="cell lines with different receptorial status, no significant difference"/>
 <result pre="the growth of A2780 cells most. Considering the two breast" exact="cancer" post="cell lines with different receptorial status, no significant difference"/>
 <result pre="the comparison of the IC50 values obtained on the two" exact="breast cancer" post="cell lines, a receptor-independent mechanism could be proposed. Results"/>
 <result pre="comparison of the IC50 values obtained on the two breast" exact="cancer" post="cell lines, a receptor-independent mechanism could be proposed. Results"/>
 <result pre="on the newly introduced benzylic moiety was also detrimental. The" exact="cancer" post="selectivity of compound 12a was tested by means of"/>
 <result pre="effect was found to be substantially lower than those against" exact="cancer" post="cell lines. Since the inhibition of proliferation was less"/>
 <result pre="triazoles (11a,bâ€&quot;15a,b) were determined on a panel of human adherent" exact="cancer" post="cell lines of gynaecological origin. MCF-7 and MDA-MB-231 were"/>
 <result pre="differing in biochemical background, while A2780 cells were isolated from" exact="ovarian cancer." post="The cancer selectivity of compound 12a was tested on"/>
 <result pre="background, while A2780 cells were isolated from ovarian cancer. The" exact="cancer" post="selectivity of compound 12a was tested on the non-cancerous"/>
 <result pre="supplements were obtained from Lonza Group Ltd., Basel, Switzerland. Near-confluent" exact="cancer" post="cells were seeded onto a 96-well microplate (5000 cells/well)"/>
 <result pre="Certain new compounds displayed potent antiproliferative action against human reproductive" exact="cancer" post="cell lines. 4-Bromo derivative 12a exerted submicromolar cell growth-inhibitory"/>
 <result pre="al.Mechanism of antiproliferative action of a new d-secoestrone-triazole derivative in" exact="cervical cancer" post="cells and its effect on cancer cell motility. J"/>
 <result pre="of antiproliferative action of a new d-secoestrone-triazole derivative in cervical" exact="cancer" post="cells and its effect on cancer cell motility. J"/>
 <result pre="d-secoestrone-triazole derivative in cervical cancer cells and its effect on" exact="cancer" post="cell motility. J Steroid Biochem Mol Biol2017;165:247â€&quot;57.27363663 16SzabÃ³J, PatakiZ,"/>
 <result pre="with uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive" exact="breast cancer" post="cells. Drug Metab Pharmacokinet2015;30:133â€&quot;41.25857231 24BanerjeeN, AllenC, BendayanR.Differential role of"/>
 <result pre="uptake of estrone-3-sulfate and cell proliferation in estrogen receptor-positive breast" exact="cancer" post="cells. Drug Metab Pharmacokinet2015;30:133â€&quot;41.25857231 24BanerjeeN, AllenC, BendayanR.Differential role of"/>
 <result pre="anion-transporting polypeptides in estrone-3-sulphate uptake by breast epithelial cells and" exact="breast cancer" post="cells. J Pharmacol Exp Ther2012;342:510â€&quot;09.22588260 25MernyÃ¡kE, SzabÃ³J, BacsaI, et"/>
 <result pre="polypeptides in estrone-3-sulphate uptake by breast epithelial cells and breast" exact="cancer" post="cells. J Pharmacol Exp Ther2012;342:510â€&quot;09.22588260 25MernyÃ¡kE, SzabÃ³J, BacsaI, et"/>
</results>
